Wyeth-Ayerst/Aviron Flumist
Executive Summary
Vaccines & Related Biological Products Advisory Committee will meet to discuss nasal influenza vaccine Flumist on July 26-27. The committee will discuss Flumist's safety and efficacy data on the first day of the meeting and the product's proposed indications on the second day. The meeting begins at 10:15 a.m. on July 26 and at 8:30 a.m. on July 27 and will be held at the Holiday Inn in Gaithersburg, Md. Wyeth told investors in April it expected the committee to review the product in July (1"The Pink Sheet" April 30, In Brief)
You may also be interested in...
Wyeth/Aviron FluMist
Nasal influenza vaccine will be reviewed by Vaccines & Related Biological Products Advisory Committee during July 26-27 meeting. The companies are seeking an indication for use in healthy children and adults. "We are hopeful about getting on the market this year, but obviously that requires FDA approval, and I think especially today, it's difficult to make firm projections about when this vaccine will be approved," AHP Chief Operating Officer Robert Essner said during an April 25 conference call. FluMist BLA was submitted Oct. 30
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials